Navigation Links
New Drug for Brain Cancer Too Dangerous for Pediatric Patients
Date:3/10/2008

Study found it caused permanent bone damage and stunted growth

MONDAY, March 10 (HealthDay News) -- A cutting-edge drug for brain cancers may place pediatric patients at risk for bone damage and stunted growth, an animal study suggests.

The new red flag concerns a signal transduction inhibitor (STI) medication known as "HhAntag", a drug developed to treat medulloblastoma brain tumors by short-circuiting tumor growth on the molecular level. The fear is that a therapy proven safe and highly successful among adults may pose a unique set of risks to young patients.

"Within just two days of treatment with HhAntag, we found a permanent shortening of bones and an alteration of joint structure among young mice," noted study co-author Tom Curran, deputy scientific director of the Stokes Research Institute at the Children's Hospital of Philadelphia.

"It's a little scary," he added. "Of course, the drug works well for about one-third of brain cancers. However, this is the first time it's really been tested in young animals. And the pathways that are targeted by this treatment are very active and important in developing children. So, we have a serious problem."

Curran and his team are publishing their findings in the March issue of Cancer Cell.

The authors noted that medulloblastoma is the most common pediatric central nervous system cancer. Although traditional non-STI treatments -- such as surgery, radiation and chemotherapy -- offer a five-year survival rate in almost four out of five children, such therapies often provoke severe side effects such as movement disorders and cognitive impairments. Those treatments are also far less effective among children under the age of 3 or among those whose disease has spread.

To date, HhAntag has achieved non-toxic results among adults -- targeting the so-called "hedgehog" pathway and shutting down a signaling mechanism critical to cancer cell prolif
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Pain in fibromyalgia is linked to changes in brain molecule
2. National Museum of Health and Medicine hosts Brain Awareness Week 2008
3. Scientists determine structure of brain receptor implicated in epilepsy and PMT
4. New findings about the brain lead to treatment for eating disturbances
5. Brain network linked to contemplation in adults is less complex in children
6. Your brain on Krispy Kremes
7. Deficit in Brain Function Puts Teens at Risk of Drug Abuse
8. Brain Scans Let Computer Read Visual Activity
9. Neural progenitor cells as reservoirs for HIV in the brain
10. Maternal love: How a mothers brain responds to her infant
11. Breast cancer subtypes linked to survival from secondary brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug for Brain Cancer Too Dangerous for Pediatric Patients
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Carnegie Science Center and Allegheny ... to develop BodyTech, a dynamic, three-pronged health and science ... new exhibit at the Science Center called BodyWorks, the ... traveling science show, Anatomy Adventure, which will hit the ... to explore a wide range of topics surrounding health ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 A ... at the American Society of Clinical Oncology (ASCO)’s ... improved survival rates for those patients who received ... regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is ... and it is already routinely used to treat ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... Pure Power Mouthguard ... , ... December 4, 2009 -- Miami dentist Dr. H.A. Nassery contributes to local athletic ... to patients. He successfully diagnosed and treated Ashley Kimmel, a student at Miami Country Day ...
... 2-D images represent, researchers say , FRIDAY, Dec. 4 ... monkeys they know, proving that they can both detect ... them before, researchers report. , The study also shows ... a photograph, the scientists authors noted. , The findings, ...
... However, benefits are not clear enough to recommend its ... News) -- Cancer patients, glaucoma patients and others can ... shows that it can help multiple sclerosis (MS) patients ... hallmark of the debilitating autoimmune disease. , "The therapeutic ...
... , LOS ANGELES, Dec. 4 Yogen Fruz , the ... holiday themed "NUmixes" -- Yog-Nog and Mint Chocolate ... unveiled at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie ... dessert alternative to indulge in this holiday season. , ...
... , BOSTON and HOUSTON, Dec. 4 AES Annual ... announced today that Vagus Nerve Stimulation (VNS) Therapy , the ... will be featured in 14 presentations at the American Epilepsy ... Hynes Convention Center in Boston, Massachusetts. , Robert Elliott, ...
... , ... InhibOx, a leading developer of novel ... MolPort, an innovator in rare chemical trading.,MolPort focuses on developing rare ... we provide this database and its updates to computational chemists at ...
Cached Medicine News:Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... 60 percent of moderate to severe patients achieved ... remission at Week 10,in data from a 54-week ... (ACG) Annual Scientific Meeting, ORLANDO, Fla., Oct. ... prospective study investigating endoscopic improvement in Crohn,s,disease (CD) ...
... Pharmacokinetic Characteristics of Naltrexone SR Associated with ... Better Tolerability in Clinical Trials ... OREX ), a biopharmaceutical company focused on the ... presented,data showing the investigational drug, Contrave(R) (naltrexone SR /,bupropion ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... The PORTERFIELD catheter incorporates six electrodes which ... from a single catheter. Positioned in the ... while recording atrial electrograms. The catheter may ... apex for atrial recording and ventricular pacing ...
Medicine Products: